AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for the treatment of Waldenström’s macroglobulinemia (WM)

 AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for the treatment of Waldenström’s macroglobulinemia (WM)

AbbVie Receives US FDA Approval for Imbruvica plus Rituximab for the treatment of Waldenström’s macroglobulinemia (WM)

 Shots:
  • Combination of Imbruvica (ibrutinib) & Rituxan (rituximab) approval is the first and only CT free combination treatment in all line of therapies 
  • This approval is based on P-III iNNOVATE (PCYC-1127) trial (N=150) assessing (Imbruvica+ Rituxan vs Rituxan alone) where PFS (82% vs 28%) with mPFS as 26.5mos and reduction in disease progression or death by 80% ·
  •  Recommended dose for Imbruvica is 420mg PO QD, while Imbruvica will be taken on prior basis before Rituxan

Click here to read full press release/ article | Ref: Abbvie | Image: Bioprocessintl

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post